Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
EDISON EQUITY RESEARCH: BAVARIAN NORDIC – ADR OUTLOOK The BMS and J&J deals, and continued Imvamune related income have provided Bavarian Nordic with validation of its vaccine...
Bavarian Nordic to receive up to $975 million, inclusive of $60 million upfront and potential exercise payment; potential development, regulatory and commercialization milestone payments;...
EDISON EQUITY RESEARCH: BAVARIAN NORDIC - STRATEGIC EBOLDA DEAL FILLS 2015 REVENUE GAP Bavarian Nordic’s $187m exclusive global licensing and supply deal for its development Ebola vaccine...
KVISTGAARD, Denmark, July 24, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that the first patient has been treated in an NCI-sponsored Phase 1 study of...
KVISTGAARD, Denmark, May 28, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that Paul Chaplin, Ph.D. has been appointed new President and CEO of the Company...
KVISTGAARD, Denmark, May 15, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today two papers featuring the combination of the Company's proprietary cancer...
KVISTGAARD, Denmark, May 14, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes its interim financial results for the first quarter of 2014. Revenue...
KVISTGAARD, Denmark, April 28, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the first patient has now been treated in a randomized, prospective Phase 2...
KVISTGAARD, Denmark, March 19, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) today published its 2013 annual report. Revenue was DKK 1,213 million / USD 224 million (DKK...
Alliance For Biosecurity Elects Chief Executive Officers Of Bavarian Nordic And Elusys Therapeutics As New Co-Chairs Leadership Team Will Advance Industry Efforts Supporting the Development of...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.1 | 1.09170305677 | 9.16 | 9.42 | 8.89 | 10820 | 9.1124152 | DR |
| 4 | 0.23 | 2.54706533776 | 9.03 | 9.42 | 8.76 | 8427 | 9.11177544 | DR |
| 12 | -0.49 | -5.02564102564 | 9.75 | 9.9 | 7.89 | 20945 | 9.00296655 | DR |
| 26 | 0.24 | 2.66075388027 | 9.02 | 15.11 | 7.89 | 57356 | 12.10105433 | DR |
| 52 | 1.66 | 21.8421052632 | 7.6 | 15.11 | 6.86 | 32120 | 11.77928592 | DR |
| 156 | -0.74 | -7.4 | 10 | 20.67 | 5.85 | 46890 | 13.21992995 | DR |
| 260 | -2.99 | -24.4081632653 | 12.25 | 20.67 | 5.04 | 37811 | 13.21708994 | DR |
| Symbol | Preis | Vol. |
|---|---|---|
| GRLFGreen Leaf Innovations Inc (PK) | US$ 0,0002 (100,00%) | 212,71M |
| GMPRGourmet Provisions International Corporation (PK) | US$ 0,0001 (0,00%) | 103,94M |
| THBDThird Bench Inc (PK) | US$ 0,0001 (-33,33%) | 94,99M |
| AITXArtificial Intelligence Technology Solutions Inc (PK) | US$ 0,0028 (-6,67%) | 79,11M |
| PHILPHI Group Inc (PK) | US$ 0,0003 (50,00%) | 74,28M |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
